AUTL Autolus Therapeutics plc
USHealthcareAs of 2026-07-10 16:00
Why AUTL matters now
Autolus Therapeutics plc (AUTL) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.61 with -4.73% on the session and $428.5M in market capitalization; recent performance reads 1-month -7.36% and YTD -24.12%.
The latest financial table shown here is Q1 2026, with revenue of $26.2M, net income of $-71.6M, and EPS of $-0.27. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -72.5%.
The latest indexable market news headline is "3 Cancer Stocks to Watch as Oncology Innovation Accelerates" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $8.00; recent insider activity includes Richardson Ryan filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.69
P/S
4.34
EV/EBITDA
-1.52
DCF Value
$-27.48
FCF Yield
-72.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-11.2%
Operating Margin
-285.9%
Net Margin
-312.0%
ROE
-128.5%
ROA
-54.8%
ROIC
-56.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $26.2M | $-71.6M | $-0.27 |
| Q4 2025 | $24.3M | $-90.2M | $-0.34 |
| FY 2025 | $75.6M | $-288.2M | $-1.08 |
| Q3 2025 | $21.2M | $-79.1M | $-0.30 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$8.87
Target (Median)
$8.00
Target Range
$7.60 - $11.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
GB
Exchange
—
Beta
2.01
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.